Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: comment on the article by Yoo.
Several lines of evidence from basic research indicate that B cells may contribute to the pathogenesis of systemic sclerosis. Clinical studies as well have provided preliminary data pointing to the direction that B-cell depletion with rituximab might be a therapeutic option for patients with this debilitating disease.
Daoussis
Dimitrios
D
Andonopoulos
Andrew P
AP
D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D017563:Lung Diseases, Interstitial / Q000150:complications / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D000069283:Rituximab; D012595:Scleroderma, Systemic / Q000150:complications / Q000188:drug therapy*
D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab